The process involves a crystalline matrix that enhances storage ability for active drugs and effectively shields them from environments that promote degradation, including the disease microenvironment. This method helped Therapyx develop a unique second-generation platform technology, EXStaM (patent pending) that allows commercial scale microencapsulation of therapeutic proteins.
Therapyx is a biotech company dedicated to the development of microparticulate therapeutics to treat infectious disease, immune-mediated inflammatory disorders, and cancer. Our collaboration with Therapyx has been ongoing since 2011.